Cymbalta Sales Data
| Rank 7 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: February 2014 (updated quarterly).
The following data shows Cymbalta U.S. retail sales in Q4 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q4 2013 | 7 ( 3) |
$1,064,186 | -23.06% | 4,595 | -25.41% |
| Q3 2013 | 4 | $1,383,170 | 3.31% | 6,160 | -7.81% |
| Q2 2013 | 4 (1) |
$1,338,912 | 3.24% | 6,682 | 2.77% |
| Q1 2013 | 3 ( 1) |
$1,296,843 | 5.65% | 6,502 | -2.09% |
| Q4 2012 | 4 | $1,227,484 | 5.97% | 6,641 | 4.07% |
| Q3 2012 | 4 (2) |
$1,158,353 | 9.50% | 6,381 | 2.34% |
| Q2 2012 | 6 (2) |
$1,057,821 | 2.77% | 6,235 | 2.20% |
| Q1 2012 | 8 (1) |
$1,029,262 | 7.58% | 6,101 | 0.66% |
| Q4 2011 | 9 | $956,723 | 4.70% | 6,061 | 3.47% |
| Q3 2011 | 9 (3) |
$913,796 | 6.08% | 5,858 | -1.53% |
| Q2 2011 | 12 (2) |
$861,431 | 5.03% | 5,949 | 4.46% |
| Q1 2011 | 10 | $820,197 | n/a | 5,695 | n/a |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
